Corvus Pharmaceuticals In... (CRVS)
| Bid | 3.6 |
| Market Cap | 239.16M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -62.29M |
| EPS (ttm) | -1.02 |
| PE Ratio (ttm) | -3.44 |
| Forward PE | -19.97 |
| Analyst | Buy |
| Ask | 3.7 |
| Volume | 504,215 |
| Avg. Volume (20D) | 724,970 |
| Open | 3.58 |
| Previous Close | 3.59 |
| Day's Range | 3.46 - 3.58 |
| 52-Week Range | 1.43 - 10.00 |
| Beta | 0.70 |
About CRVS
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat pa...
Analyst Forecast
According to 3 analyst ratings, the average rating for CRVS stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 327.35% from the latest price.
Stock Forecasts
1 month ago · seekingalpha.com
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call TranscriptCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q4 2024 Earnings Conference Call March 25, 2025 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Leiv Lea - CFO Richard Miller - CEO Conferen...